Company: BGLC
Filing Date: 2025-12-02
Form Type: 8-K
Source: 0001477932-25-008724
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-12-02
Form: 8-K
Item: Item 7.01
Chunk 2
---
Item 7.01. Regulation FD Disclosure.

On December 1, 2025, the Company issued a press release announcing its execution of the Exclusive Intellectual Property License Agreement with Fidelion relating to the VitaGuard™ MRD platform.

On December 2, 2025, the Company intends to issue a press release announcing its entry into the $500,000,000 Equity Purchase Agreement with ARC.

Copies of both press releases are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in this Item 7.01 and Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statement and Exhibits.